Drugs / RAZPIPADON
RAZPIPADON
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 missed | ||||||
| Phase 1 | NCT02565628 | Nov 2015 → May 2016 | Parkinson disease | Pfizer | Completed | Missed primary |
| Phase 1 | NCT02184429 | Jul 2014 → Mar 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04958031 | Jun 2021 → Feb 2025 | — | AbbVie | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-15 | AbbVie | Regulatory Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy abbvie.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAZPIPADON | ChEMBL registry synonym — accepted as the source's own label CHEMBL3697578 ↗ |
| Known as | CVL-871 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04958031 ↗ |
| Known as | PF-06669571 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02184429 ↗ |
| Known as | PW-0464, (-)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL3697578 ↗ |
| Action | Activate | “dopamine D1 receptor partial agonist” PMID 29478239 ↗ Jun 2018 |
| Modality | Small molecule | — CHEMBL3697578 ↗ |
| Route | Oral | “Oral dosing of 0.15 mg PF-06669571” NCT02184429 ↗ |